Research Article

Dysregulated microRNAs in laryngeal cancer: a comprehensive meta-analysis using a robust rank aggregation approach

Zhejiang University, Zhejiang Province, 310003, PR China

Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province, 310003, PR China

Search for more papers by this author

Yu Guo

Zhejiang University, Zhejiang Province, 310003, PR China

Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province, 310003, PR China

Search for more papers by this author

Yinjie Ao

Zhejiang University, Zhejiang Province, 310003, PR China

Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province, 310003, PR China

Search for more papers by this author

Shuihong Zhou

*Author for correspondence:

E-mail Address: 1190051@zju.edu.cn

https://orcid.org/0000-0002-7163-2289

Zhejiang University, Zhejiang Province, 310003, PR China

Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang Province, 310003, PR China

Search for more papers by this author

Published Online:19 Aug 2020https://doi.org/10.2217/fon-2020-0394

View article

Abstract

We need a reasonable method of compiling data from different studies regarding the expression of microRNA (miRNA) in laryngeal squamous cell carcinoma (LSCC). The robust rank aggregation method was used to integrate the rank lists of miRNAs from 11 studies. The enrichment analysis was performed on target genes of meta-signature miRNAs. The Cancer Genome Atlas database was used to confirm the results of meta-analysis. Three meta-signature miRNAs (miR-21-5p, miR-196a-5p and miR-145-5p) were obtained. All three miRNAs could be prognostic for LSCC. The enrichment analysis showed that these miRNAs were associated significantly with multiple cancer-related signaling pathways. The robust rank aggregation approach is an effective way to identify important miRNAs from different studies. All identified miRNAs could be candidates for LSCC diagnostic and prognostic biomarkers.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Gamez ME, Blakaj A, Zoller W, Bonomi M, Blakaj DM. Emerging concepts and novel strategies in radiation therapy for laryngeal cancer management. Cancers (Basel) 12(6), E1651 (2020).
Medline CASGoogle Scholar
2. Obid R, Redlich M, Tomeh C. The treatment of laryngeal cancer. Oral Maxillofac. Surg. Clin. North Am. 31(1), 1–11 (2019).
MedlineGoogle Scholar
3. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 107(7), 823–826 (2001).
Medline CASGoogle Scholar
4. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 302(1), 1–12 (2007).
Medline CASGoogle Scholar
5. Võsa U, Kolde R, Vilo J, Metspalu A, Annilo T. Comprehensive meta-analysis of microRNA expression using a robust rank aggregation approach. Methods Mol. Biol. 1182, 361–373 (2014). • This article describes the principle of robust rank aggregation (RRA) and the implementation code in detail.
MedlineGoogle Scholar
6. Naorem LD, Muthaiyan M, Venkatesan A. Identification of dysregulated miRNAs in triple negative breast cancer: a meta-analysis approach. J. Cell. Physiol. 234(7), 11768–11779 (2019).
Medline CASGoogle Scholar
7. Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. Int. J. Cancer 132(12), 2884–2893 (2013). • This article also describes the RRA method in detail.
Medline CASGoogle Scholar
8. Wang M, Xie R, Si H, Shen B. Integrated bioinformatics analysis of miRNA expression in osteosarcoma. Artif. Cells Nanomed. Biotechnol. 45(5), 936–943 (2017).
Medline CASGoogle Scholar
9. Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics 28(4), 573–580 (2012).
Medline CASGoogle Scholar
10. Zhang C, Gao W, Wen S et al. Potential key molecular correlations in laryngeal squamous cell carcinoma revealed by integrated analysis of mRNA, miRNA and lncRNA microarray profiles. Neoplasma. 63(6), 888–900 (2016).
Medline CASGoogle Scholar
11. Zhao R, Li FQ, Tian LLTian LL et al. Comprehensive analysis of the whole coding and non-coding RNA transcriptome expression profiles and construction of the circRNA-lncRNA co-regulated ceRNA network in laryngeal squamous cell carcinoma. Funct. Integr. Genomics. 19(1), 109–121 (2019).
Medline CASGoogle Scholar
12. Ekmekci CG, Coskunpinar E, Avci H, Farooqi AA, Orhan KS, Akbas F. Integrative analysis of mRNA and microRNA expression profiles in laryngeal squamous cell carcinoma. J. Cell Biochem. 120(3), 3415–3422 (2019).
Medline CASGoogle Scholar
13. Janiszewska J, Szaumkessel M, Kostrzewska-Poczekaj M et al. Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE.. 10(12), e0144924(2015).
MedlineGoogle Scholar
14. Zhang T, Han G, Wang Y, Chen K, Sun Y. MicroRNA expression profiles in supraglottic carcinoma. Oncol. Rep. 31(5), 2029–2034 (2014).
Medline CASGoogle Scholar
15. Sun X, Song Y, Tai X, Liu B, Ji W. MicroRNA expression and its detection in human supraglottic laryngeal squamous cell carcinoma. Biomed Rep. 1(5), 743–746 (2013).
Medline CASGoogle Scholar
16. Cao P, Zhou L, Zhang J et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 35(5), 720–728 (2013).
MedlineGoogle Scholar
17. Petrović N. MiR-21 might be involved in breast cancer promotion and invasion rather than in initial events of breast cancer development. Mol. Diagn. Ther. 20(2), 97–110 (2016).
Medline CASGoogle Scholar
18. Wu Y, Song Y, Xiong Y et al. MicroRNA-21 (miR-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell. Physiol. Biochem. 43(3), 945–958 (2017).
Medline CASGoogle Scholar
19. Zhou B, Wang D, Sun G, Mei F, Cui Y, Xu H. Effect of miR-21 on apoptosis in lung cancer cell through inhibiting the PI3K/Akt/NF-κB signaling pathway in vitro and in vivo. Cell. Physiol. Biochem. 46(3), 999–1008 (2018).
Medline CASGoogle Scholar
20. Cao P, Zhou L, Zhang J et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 35(5), 720–728 (2013).
MedlineGoogle Scholar
21. Liu J, Lei D-P, Jin T, Zhao X-N, Li G, Pan X-L. Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pac. J. Cancer Prev. 12(10), 2653–2657 (2011). •• This article describes the role of miR-21-5p in laryngeal squamous cell carcinoma (LSCC); miR-21-5p is significantly related to the clinical characteristics of LSCC.
MedlineGoogle Scholar
22. Hu A, Huang J-J, Xu W-H et al. MiR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am. J. Transl. Res. 6(5), 604–613 (2014).
Medline CASGoogle Scholar
23. Avissar M, McClean MD, Kelsey KT, Marsit CJ. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 30(12), 2059–2063 (2009).
Medline CASGoogle Scholar
24. Fu X, Han Y, Wu Y et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest. 41(11), 1245–1253 (2011).
Medline CASGoogle Scholar
25. Liu M, Wu H, Liu T et al. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 19(7), 828–837 (2009).
Medline CASGoogle Scholar
26. Xu Y-T, Chen R-Q, Lin G-B et al. Defining the regulatory role of programmed cell death 4 in laryngeal squamous cell carcinoma. Biochem. Cell Biol. 96(5), 522–538 (2018).
Medline CASGoogle Scholar
27. Saito K, Inagaki K, Kamimoto T et al. MicroRNA-196a is a putative diagnostic biomarker and therapeutic target for laryngeal cancer. PLoS ONE 8(8), e71480–e71480 (2013).
Medline CASGoogle Scholar
28. Jin C, Zhang Y, Li J. Upregulation of MiR-196a promotes cell proliferation by downregulating p27(kip1) in laryngeal cancer. Biol. Res. 49(1), 40–40 (2016). •• This article describes the role of miR-196a-5p in LSCC; miR-196a-5p can promote the proliferation by downregulating p27kip1 in LSCC.
MedlineGoogle Scholar
29. Iorio MV, Ferracin M, Liu C-G et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065–7070 (2005).
Medline CASGoogle Scholar
30. Kano M, Seki N, Kikkawa N et al. MiR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int. J. Cancer 127(12), 2804–2814 (2010).
Medline CASGoogle Scholar
31. Sewer A, Kogel U, Talikka M et al. Evaluation of the tobacco heating system 2.2 (THS2.2). Part 5: microRNA expression from a 90-day rat inhalation study indicates that exposure to THS2.2 aerosol causes reduced effects on lung tissue compared with cigarette smoke. Regul. Toxicol. Pharmacol. 81(Suppl. 2), S82–S92 (2016).
Medline CASGoogle Scholar
32. Karatas OF, Yuceturk B, Suer I et al. Role of miR-145 in human laryngeal squamous cell carcinoma. Head Neck 38(2), 260–266 (2016). •• This article describes the role of miR-145-5p in LSCC; miR-145-5p could be an important regulator of SOX2.
MedlineGoogle Scholar
33. Karatas OF, Suer I, Yuceturk B et al. The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells. Tumour Biol. 37(3), 4183–4192 (2016).
Medline CASGoogle Scholar
34. Ye D, Zhou C, Deng H, Lin L, Zhou S. MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway. Cancer Manag. Res. 11, 3801–3812 (2019). • This article was previously published by our team and reveals the important role of miR-145-5p in the growth of laryngeal cancer.
Medline CASGoogle Scholar
35. Gao W, Zhang C, Li W et al. Promoter methylation–regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol. Ther. 27(2), 365–379 (2019).
Medline CASGoogle Scholar

Vol. 16, No. 33

Supplemental Materials

Metrics

Downloaded 142 times

History

Received 22 April 2020

Accepted 17 July 2020

Published online 19 August 2020

Published in print November 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paperplease visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0394

Author contributions

Z Cao and S Zhou designed and wrote the paper; Z Cao and Y Guo collected the related studies; Z Cao and Y Ao analyzed the datasets and made the figures and tables.

Acknowledgments

The authors thank all members of the otolaryngology department for their kind support.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Data sharing statement

The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them and that the use of these shared data is in accordance with the terms (if any) agreed on upon their receipt. The sources of data include the TCGA database, GSE70289, GSE70289, GSE47610, GSE62819 and GSE124679.

PDF download